Dispense per farmacologia - Azienda ULSS 21

More documents

Recommendations

Info

DIU 13/10/10 Tiazidi: usi § i<strong>per</strong>tensione (diuresi salina) § scompenso (metalazone) Controindicazioni: IRC diabete i<strong>per</strong>uricemia tendenza a ipokaliemia
DIU 13/10/10 2) Drastici o dell’ansa Furosemide (lasix 25, 500 mg, f 20-250 mg) Torasemide (toradiur, diuresix 10 mg, f 10 mg) Piretanide (tauliz 3-6 mg) FAD blocco riass Na Cl ansa di Henle => acqua segue Gran flusso di acqua: "poliuria pallida" Fuori: K, H, Mg, Cl, Ca, ac urico Anche lievi vasodilatatori (ok EPA e SCO)
Page 1 and 2:
13/10/10 FARMACOLOGIA
Page 3 and 4: Farmaco-cinetica (FAK) Farmaco-dina
Page 5 and 6: 13/10/10 FAK: assorbimento Attraver
Page 7 and 8: 1 c xos (somm. Isolata) x = tempo y
Page 9 and 10: FAK: Velocità di eliminazione 13/1
Page 11 and 12: FAK: steady state (SS) = situazione
Page 13 and 14: Dose xos 1 c /day: 2 dosaggi 13/10/
Page 15 and 16: Overdose xos 13/10/10
Page 17 and 18: 13/10/10 INOTROPI Digitale Amine ad
Page 19 and 20: INO FAD 13/10/10 Digossina: FAD §
Page 21 and 22: INO Intossicazione digitalica VN: 0
Page 23 and 24: INO Amine adrenergiche (o simpatico
Page 25 and 26: INO § Noradrenalina 13/10/10 Amine
Page 27 and 28: INO § Dopamina (revivan) f 200 mg
Page 29 and 30: 13/10/10 [NB - Ibopamina (inocor, s
Page 31 and 32: INO 13/10/10 Enoximone Enoximone (p
Page 33 and 34: INO Mortalità e morbilità Digital
Page 35 and 36: INO 13/10/10 Beta-2 agonisti Su rec
Page 37 and 38: INO NB - Recettori adrenergici α p
Page 39 and 40: loc 13/10/10 Alfa-bloccanti § Doxa
Page 41 and 42: loc 13/10/10 Beta-bloccanti Propran
Page 43 and 44: loc 13/10/10 Azione dei beta-blocca
Page 45 and 46: loc Farmacodinamica 13/10/10 Inibiz
Page 47 and 48: loc Mortalità e morbilità 13/10/1
Page 49 and 50: DIU Tiazidi Drastici o dell’ansa
Page 51 and 52: DIU FAD 13/10/10 Tiazidi (segue) in
Page 53: DIU 13/10/10 Metalazone e indapamid
Page 57 and 58: DIU 13/10/10 USI § Scompenso cardi
Page 59 and 60: DIU 3) Risparmiatori di potassio Sp
Page 61 and 62: DIU Altri risparmiatori di K Canren
Page 63 and 64: DIU 13/10/10 4) Osmotici Glicerolo
Page 65 and 66: Caa Classificazione § calcio-selet
Page 67 and 68: Caa Ca-antag. diidropiridinici FAD
Page 69 and 70: Caa 13/10/10 Diidro-piridine: usi
Page 71 and 72: Caa 13/10/10 Farmacocinetica Nifedi
Page 73 and 74: Caa Verapamil etc: FAD FAD Blocco c
Page 75 and 76: Caa Verapamil etc: usi § aritmie #
Page 77 and 78: Caa FARMACOCINETICA 13/10/10 Verapa
Page 79 and 80: ACEI ACE-INIBITORI Captopril (capot
Page 81 and 82: ACEI ACEI: farmacodinamica Renina
Page 83 and 84: ACEI 13/10/10 ACE: FAD 2 No degrada
Page 85 and 86: ACEI § ipertensione 13/10/10 ACEI:
Page 87 and 88: ACEI ACEI: effetti indesiderati §
Page 89 and 90: ARB Losartan (lortaan, losaprex, ne
Page 91 and 92: ARB Inibitori di angiotensina II "s
Page 93 and 94: ARB . . . tranne: § no tosse § bl
Page 95 and 96: ARB 13/10/10 Sartani: usi Gli stess
Page 97 and 98: ARB Sartani: effetti indesiderati
Page 99 and 100: 13/10/10 ANTI-RENINICI § Aliskiren
Page 101 and 102: NITRO Nitro-derivati: FAD 13/10/10
Page 103 and 104: NITRO Nitrati: usi § angina pector
Page 105 and 106:
NITRO Nitrati: farmaco-cinetica xos
Page 107 and 108:
ANG Elenco antianginosi § nitroder
Page 109 and 110:
ANG AZIONI 13/10/10 Nitrati: azioni
Page 111 and 112:
ANG 13/10/10 2) Beta-bloccanti Anti
Page 113 and 114:
ANG 4) Altri anti-anginosi § trime
Page 115 and 116:
ANG § ivabradina (procoralan, corl
Page 117 and 118:
IPT 13/10/10 IPERTENSIONE (IPT) Pre
Page 119 and 120:
IPT Anti-ipt: punti di azione 13/10
Page 121 and 122:
IPT 1) Anti-adrenergici centrali 1)
Page 123 and 124:
IPT § Doxazosina (cardura) § Tera
Page 125 and 126:
IPT 4) Vaso-dilatatori diretti Cate
Page 127 and 128:
IPT 13/10/10 6) Diuretici Abbinabil
Page 129 and 130:
IPT 13/10/10 8) Sartani Stesse indi
Page 131 and 132:
ACG 13/10/10 ANTI-COAGULANTI (in se
Page 133 and 134:
ACG 3) fase plasmatica Via intrinse
Page 135 and 136:
ACG Schema fibrinolisi 13/10/10
Page 137 and 138:
ACG 1) Antiaggreganti piastrinici b
Page 139 and 140:
ACG Sindrome di Reye = encefalopati
Page 141 and 142:
ACG § ticlopidina (tiklid, aplaket
Page 143 and 144:
ACG § prasugrel Simile a clopidogr
Page 145 and 146:
ACG Effetti indesiderati: emorragia
Page 147 and 148:
ACG 13/10/10
Page 149 and 150:
ACG 13/10/10 Fondaparinux Fondapari
Page 151 and 152:
ACG Effetti indesiderati Emorragie
Page 153 and 154:
ACG 13/10/10 Indicazioni TVP: profi
Page 155 and 156:
ACG 4) Antitrombinici diretti Endov
Page 157 and 158:
ACG Antitrombinici diretti xos § x
Page 159 and 160:
ACG GP IIb/IIIa: via finale comune
Page 161 and 162:
ACG 13/10/10 infarto, INDICAZIONI:
Page 163 and 164:
ACG § urokinasi (urokinasi, alfaki
Page 165 and 166:
ACG § reteplase (rapilysin, f 10 U
Page 167 and 168:
ACG 7) Pro-coagulanti a) anti-emorr
Page 169 and 170:
13/10/10 ANTI-ARITMICI
Page 171 and 172:
ARI 13/10/10 Elettrogenesi aritmie
Page 173 and 174:
B - IPOCINETICHE Scappamento, BSA,
Page 175 and 176:
ARI 13/10/10 Farmaci classe I Rendo
Page 177 and 178:
ARI 13/10/10 Disopiramide Disopiram
Page 179 and 180:
ARI 13/10/10 mexiletina Mexiletina
Page 181 and 182:
ARI 13/10/10 flecainide Flecainide
Page 183 and 184:
ARI Classe II: beta-bloccanti IND:
Page 185 and 186:
ARI Classe III § Amiodarone (corda
Page 187 and 188:
ARI § Dronedarone (multaq, 400 mg)
Page 189 and 190:
ARI 13/10/10 Classe IV: ca-antagoni
Page 191 and 192:
ARI Inibisce l'effetto vagale 13/10
Page 193 and 194:
ARI 13/10/10 digitale Digossina (la
Page 195 and 196:
13/10/10 Fine aritmie
Page 197 and 198:
LIP 13/10/10 Colesterolo Trigliceri
Page 199 and 200:
LIP 13/10/10 Dislipidemie Tipo 1 ip
Page 201 and 202:
LIP 13/10/10 ATP panel LDL ________
Page 203 and 204:
LIP 13/10/10 1) Statine Atorvastati
Page 205 and 206:
LIP Effetti indesiderati 13/10/10 S
Page 207 and 208:
LIP 3) Acido nicotinico § Ac. nico
Page 209 and 210:
LIP Fibrati FAD inib lipolisi del t
Page 211 and 212:
LIP 6) Ac grassi omega 3 § seacor,
Page 213 and 214:
DM LIP 13/10/10 1) sulfanil-uree St
Page 215 and 216:
D M 3) inibitori assorbimento intes
Page 217 and 218:
D M 13/10/10 5) metiglinidi Aumenta
Page 219 and 220:
D M 7) amilino-mimetici § pramlint
show all

Dispense per farmacologia - Azienda ULSS 21

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?